Children's Medical Center Receives Patent for Thiazole Amide Compounds as Vaccine Adjuvants
Summary
The USPTO granted patent US12611456B2 to Children's Medical Center Corporation on April 28, 2026, covering thiazole amide compounds for modulating human immune response. The patented compounds function as adjuvants in vaccines and are intended for treating and/or preventing diseases including proliferative, inflammatory, autoimmune, infectious, and chronic diseases. The patent names David J. Dowling, Ofer Levy, and Francesco Borriello as inventors and includes 19 claims. This represents a routine IP event granting exclusivity to the assignee for the disclosed compound class and its applications.
“Provided herein are thiazole amide compounds (e.g., Formula (I)) for use in enhancing human immune response and/or as adjuvants in vaccines.”
About this source
USPTO classification A61P covers the therapeutic use of compounds: indications like cancer, inflammation, cardiovascular disease, CNS disorders, and rare diseases. Every patent grant in A61P lands in this feed, around 190 a month, with the patent number, title, applicant, inventor names, and abstract. A61P grants are frequently co-classified with composition-of-matter patents, so this feed is especially useful for mapping which chemical entities have secured both composition and method-of-use protection. Watch this if you run drug discovery, advise on biotech patent portfolios, scout in-licensing opportunities, or track antibody-drug conjugate and small-molecule oncology patent activity.
What changed
The USPTO issued patent US12611456B2 to Children's Medical Center Corporation for thiazole amide compounds described as enhancers of innate and/or adaptive immune response. The patent covers use of these compounds as adjuvants in vaccines for treating or preventing proliferative, inflammatory, autoimmune, infectious, or chronic diseases, along with related pharmaceutical compositions and methods.
Affected parties include pharmaceutical companies developing vaccine adjuvant technologies, immunotherapeutic developers, and researchers in the infectious disease and immunology fields. The patent grants 20-year exclusivity from the September 2020 filing date, potentially restricting independent development of similar thiazole amide immune modulators until 2040 unless alternative compounds or uses are identified.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Use of thiazole amide compounds for modulating human immune response
Grant US12611456B2 Kind: B2 Apr 28, 2026
Assignee
Children's Medical Center Corporation
Inventors
David J. Dowling, Ofer Levy, Francesco Borriello
Abstract
Provided herein are thiazole amide compounds (e.g., Formula (I)) for use in enhancing human immune response and/or as adjuvants in vaccines. The compounds described herein are used as enhancers of an immune response (e.g., innate and/or adaptive immune response), and are useful in treating and/or preventing a disease, as adjuvants in a vaccine for the disease, (e.g., proliferative disease, inflammatory disease, autoimmune disease, infectious disease, or chronic disease). Also provided in the present disclosure are compositions (e.g., pharmaceutical composition), kits, methods, and uses including or using compounds described herein.
CPC Classifications
A61K 39/39 A61K 31/426 A61K 31/428 A61K 39/0011 A61K 2039/55505 A61K 2039/55511 A61K 2039/55566 A61P 37/04 Y02A 50/30
Filing Date
2020-09-16
Application No.
17761158
Claims
19
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.